ATXI
Avenue Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.54
−4.48%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | 1.4M | — | — | — |
| Cost of Revenue | — | — | — | — | — |
| Gross Profit | (1.4M) | 1.4M | — | — | — |
| Operating Expenses | |||||
| R&D Expense | 881.0K | 1.0M | 6.6M | 10.4M | 2.7M |
| SG&A Expense | 2.2M | 3.7M | 4.6M | 4.2M | 5.3M |
| General & Admin Expense | 2.2M | 3.7M | 4.6M | 4.2M | 5.3M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 3.1M | 4.7M | 11.3M | 14.5M | 8.0M |
| Cost and Expenses | 3.1M | 4.7M | 11.3M | 14.5M | 8.0M |
| Operating Income (EBIT) | (3.1M) | (3.3M) | (11.3M) | (14.5M) | (8.0M) |
| Non-Operating | |||||
| Interest Income | 93.0K | 121.0K | 176.0K | 126.0K | 20.0K |
| Interest Expense | — | — | — | — | 1.2M |
| Net Interest Income | 93.0K | 121.0K | 176.0K | 126.0K | (1.1M) |
| Other Non-Op Income/Expense | 296.0K | 339.0K | (413.0K) | 4.1M | 4.4M |
| Non-Operating Income (excl Interest) | (41.0K) | — | 413.0K | (4.1M) | (5.6M) |
| EBT (Pre-Tax Income) | (2.8M) | (2.9M) | (11.7M) | (10.5M) | (3.6M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (2.8M) | (2.9M) | (11.7M) | (10.4M) | (3.6M) |
| Earnings from Cont. Ops | (2.8M) | (2.9M) | (11.7M) | (10.5M) | (3.6M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (2.8M) | (2.9M) | (11.7M) | (10.4M) | (3.6M) |
| Per Share | |||||
| Basic EPS | ($0.85) | ($0.93) | ($0.90) | ($73.60) | ($121.91) |
| Diluted EPS | ($0.85) | ($0.93) | ($0.90) | ($73.48) | ($121.91) |
| Revenue Per Share | $0.00 | $0.45 | $0.00 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 3.3M | 3.1M | 13.0M | 141000 | 29135 |
| Diluted Shares Outstanding | 3.3M | 3.1M | 13.0M | 141221 | 29135 |
| Profitability Metrics | |||||
| EBITDA | (3.1M) | (3.3M) | (11.7M) | 4.1M | (2.4M) |
| D&A | — | — | — | 14.5M | — |
| EBIT | (3.1M) | (3.3M) | (11.7M) | (10.5M) | (2.4M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026